New anti-clotting drugs jostle for market shareNew drugs to prevent dangerous blood clots promise to shake up the market but pharmaceutical companies face an uphill fight on price. Cost will be key for both AstraZeneca's Brilinta and Boehringer Ingelheim's Pradaxa as they jostle for sa More… |
Boehringer stroke drug proves a winner in trialPatients at risk of stroke due to an erratic heartbeat should soon have a viable alternative to 50-year-old warfarin, after a new pill from Boehringer Ingelheim beat expectations in a major clinical study. The strong showing for the unlist More… |